Key Points Past clues point to the Vanguard S&P 500 ETF being Buffett's favorite exchange-traded fund.The legendary investor isn't buying his favorite ETF because of a dangerously high ...

The tech leader has lagged the market this year and trades at attractive levels relative to its growth potential, making the stock a no-brainer buy today. Where to invest $1,000 right now? Our analyst ...

Unilever's stock and cash flow rise via price hikes, yet real growth lags. Read here for UL stock's Growth Action Plan's ...

Fuchs SE is backed by R&D, market share growth, and megatrends like e-mobility, it thrives amidst risks. See here to know why ...

Whereas the average S&P 500 bear market has resolved in 286 calendar days (about 9.5 months) over a nearly 94-year period, ...

Wall Street closed its third winning week in the last four with a quiet finish on Friday. The S&P 500 edged down by a whisper ...

One of biotech’s highest fliers, Sarepta Therapeutics, lost more than a third of its market value on Friday after executives said that one of its experimental gene-replacement therapies was linked to ...

WY Biotech is now obligated to pay a $7 million upfront license fee to HCW Biologics by Sept. 30, according to a filing with the Securities and Exchange Commission. HCW Biologics previously said it ...

Stocks turned in a lackluster performance Friday as Wall Street took a breather at the end of the first week of ...

Comerica (NYSE:CMA) reported its Q2 2025 earnings on July 18, reporting EPS of $1.42 (up nearly 14% sequentially). In the quarter, it returned $193 million to shareholders through stock repurchases ...